Clinical Trial Update: A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study of AMG 701 as monotherapy or with pomalidomide, with or without dexamethasone, in relapsed/refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AMG 701
• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Amgen | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1 | Status: TERMINATED